Black Creek Investment Management Inc. Sells 788,830 Shares of Grifols, S.A. $GRFS

Black Creek Investment Management Inc. cut its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 7.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,257,127 shares of the biotechnology company’s stock after selling 788,830 shares during the quarter. Grifols accounts for about 4.3% of Black Creek Investment Management Inc.’s investment portfolio, making the stock its 11th largest holding. Black Creek Investment Management Inc.’s holdings in Grifols were worth $86,554,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of GRFS. Bank of Montreal Can boosted its holdings in Grifols by 3,205.1% during the 3rd quarter. Bank of Montreal Can now owns 3,013,723 shares of the biotechnology company’s stock valued at $30,017,000 after acquiring an additional 2,922,540 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in Grifols by 383.7% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,800,645 shares of the biotechnology company’s stock worth $27,894,000 after buying an additional 2,221,633 shares during the period. Norges Bank purchased a new stake in Grifols in the 4th quarter worth approximately $18,139,000. Brandes Investment Partners LP raised its position in shares of Grifols by 6.3% in the 4th quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company’s stock worth $289,422,000 after acquiring an additional 1,838,727 shares in the last quarter. Finally, Capital World Investors raised its position in shares of Grifols by 5.9% in the 3rd quarter. Capital World Investors now owns 22,926,140 shares of the biotechnology company’s stock worth $228,344,000 after acquiring an additional 1,273,391 shares in the last quarter.

Grifols Stock Up 2.0%

Shares of NASDAQ:GRFS opened at $7.64 on Friday. Grifols, S.A. has a 52-week low of $7.26 and a 52-week high of $11.14. The firm has a market capitalization of $5.20 billion, a P/E ratio of 40.21, a P/E/G ratio of 0.30 and a beta of 0.65. The stock has a 50 day moving average price of $8.01 and a 200-day moving average price of $8.56. The company has a debt-to-equity ratio of 1.16, a quick ratio of 0.85 and a current ratio of 2.47.

Grifols (NASDAQ:GRFS) last announced its earnings results on Saturday, February 14th. The biotechnology company reported $0.38 earnings per share (EPS) for the quarter. Grifols had a return on equity of 6.21% and a net margin of 5.54%.The firm had revenue of $2.32 billion during the quarter. As a group, equities research analysts anticipate that Grifols, S.A. will post 1.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GRFS has been the subject of several research reports. Wall Street Zen lowered Grifols from a “buy” rating to a “hold” rating in a research report on Monday, May 18th. Weiss Ratings raised Grifols from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. Finally, Zacks Research lowered Grifols from a “hold” rating to a “strong sell” rating in a research report on Friday, May 8th. Three research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Grifols has a consensus rating of “Reduce” and an average target price of $10.00.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.